



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/565,116

01/17/2006

Jean Woloszko

A-22

6140

21394 7590 08/03/2011

ARTHROCARE CORPORATION

ATTN: Matthew Scheele

7500 Rialto Boulevard

Building Two, Suite 100

Austin, TX 78735-8532

EXAMINER

HUPCZEY, JR, RONALD JAMES

ART UNIT

PAPER NUMBER

3739

NOTIFICATION DATE

DELIVERY MODE

08/03/2011

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

intel_prop@arthrocare.com



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address : COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
10/565,116	17 January 2006	WOLOSZKO ET AL.	A-22

ARTHROCARE CORPORATION
ATTN: Matthew Scheele
7500 Rialto Boulevard
Building Two, Suite 100
Austin, TX 78735-8532

EXAMINER

RONALD HUPCZEY, JR

ART UNIT

PAPER

3739

20110728

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

1. Applicant's information disclosure statement of July 26th, 2011 was filed after the issue fee was paid. Information disclosure statements filed after payment of the issue fee ***will not be considered, but will be placed in the file***. However, the application may be withdrawn from issue in order to file a request for continued examination (RCE) under 37 CFR 1.114 upon the grant of a petition under 37 CFR 1.313(c)(2), or a continuing application under 37 CFR 1.53(b) (or a continued prosecution application (CPA) under 37 CFR 1.53(d) if the CPA is for a design patent and the prior application of the CPA is a design application) upon the grant of a petition filed under the provisions of 37 CFR 1.313(c)(3). Alternatively, the other provisions of 37 CFR 1.313 may apply, e.g., a petition to withdraw the application from issue under the provisions of 37 CFR 1.313(c)(1) may be filed together with an unequivocal statement by the applicant that one or more claims are unpatentable over the information contained in the statement. The information disclosure statement would then be considered upon withdrawal of the application from issue under 37 CFR 1.313(c)(1).

Please note the attachment to this communication of the lined-through copy of the IDS submitted July 26th, 2011.

/Ronald J. Hupczey/
Examiner, Art Unit 3739

/Michael Peffley/
Primary Examiner, Art Unit 3739